Pomerantz LLP announced a class action lawsuit against Replimune Group following the FDA's rejection of its Biologics License Application for RP1 combined with nivolumab due to study deficiencies. The FDA criticized the clinical trials as inadequate and highlighted unaddressed study design concerns. After the FDA's April 10, 2026 announcement, Replimune's stock dropped nearly 20%, then fell an additional 64% after the company’s press release. Investors who bought Replimune shares during the class period have until October 5, 2026, to seek lead plaintiff status in the lawsuit.
Replimune Group shares are the subject of this update. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 25, 2026 03:02 WIB: 33 of 100 priced US health stocks rose, 67 fell. Notable movers include DGX at USD 232.90 with a -5.51% change, CRSP at USD 55.93 down 5.25% but with 100% buy orders, and RXRX at USD 3.88 up 4.86% with 100% buy orders and a typical hold time of 22 days.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
REGENXBIO announced positive 3-year results from its Phase II ALTITUDE trial of surabgene lomparvovec (sura-vec) for non-proliferative diabetic retinopathy (NPDR). A single in-office gene therapy dose led to over 60% of participants achieving more th...
Ethereum (ETH) has printed its first higher high since its August 2025 peak, breaking a year-long pattern of lower highs. It surpassed the $2,438 resistance level, which has now turned into support, signaling a more bullish weekly structure. However,...
